Summary
The Trump administration is working on a deal to allow Medicare to cover certain weight loss drugs from companies Eli Lilly and Novo Nordisk. This deal could reduce costs and expand access to these drugs for seniors. The decision might also influence private insurance companies' coverage decisions.
Key Facts
- The deal involves Medicare covering weight loss drugs from Eli Lilly and Novo Nordisk.
- Eli Lilly's drug, Zepbound, could cost $299, and Novo Nordisk's drug, Wegovy, could cost $149 for the lowest dose on the TrumpRX website.
- The deal aims to lower prices and expand access for seniors.
- Medicare's decision could influence private insurers to cover these drugs as well.
- Medicaid might also cover the drugs if the deal goes through.
- Medicare currently covers similar drugs for conditions like diabetes and heart disease.
- Earlier, a Biden-era plan to cover obesity treatments under Medicare and Medicaid was scrapped.
- The story is developing, and more updates are expected.
